COMPANY
Bolder Biotechnology Inc.
BOLDER BIOTECHNOLOGY INC has received NIH funding, most recently in fiscal 2024 for the project “Novel drug combinations for improving survival from acute radiation syndrome when administered 48 hours post- irradiation”. From public records Source · Oct 12, 2026
NIH awards 50
- NIH award 5R44AI142909-04 FY2024: $717,432 awarded for that fiscal year; activity R44 (SBIR); PI COX, GEORGE NORBERT; recipient as written: BOLDER BIOTECHNOLOGY, INC., BOULDER, CO. Novel drug combinations for improvi source ↗
- NIH award 1R43AI181293-01 FY2024: $295,924 awarded for that fiscal year; activity R43 (SBIR); PI COX, GEORGE NORBERT; recipient as written: BOLDER BIOTECHNOLOGY, INC., BOULDER, CO. Improving survival from Burkholderi source ↗
- NIH contract (government contract; not a grant and not an investment round) 75N93023C00011-P00002-9999-1 FY2024: $1,428,550 awarded for that fiscal year; activity N01 (OTHER_NIH); PI COX, GEORGE; recipient as written: BOLDER BIOTECHNOLOGY, INC., BOULDER, CO. A source ↗
- NIH award 2R44AI142909-03 FY2023: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI COX, GEORGE NORBERT; recipient as written: BOLDER BIOTECHNOLOGY, INC., BOULDER, CO. Novel drug combinations for impro source ↗
- NIH contract (government contract; not a grant and not an investment round) 75N93023C00011-0-9999-1 FY2023: $1,650,819 awarded for that fiscal year; activity N01 (OTHER_NIH); PI COX, GEORGE; recipient as written: BOLDER BIOTECHNOLOGY, INC., BOULDER, CO. ADVANC source ↗
- NIH award 1R43AI157684-01A1 FY2021: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI COX, GEORGE NORBERT; recipient as written: BOLDER BIOTECHNOLOGY, INC., BOULDER, CO. Stimulating innate immunity to pr source ↗
- NIH award 5R43AI142909-02 FY2020: $293,507 awarded for that fiscal year; activity R43 (SBIR); PI COX, GEORGE NORBERT; recipient as written: BOLDER BIOTECHNOLOGY, INC., BOULDER, CO. Novel drugs combinations for improv source ↗
- NIH award 1R43AI142909-01A1 FY2019: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI COX, GEORGE NORBERT; recipient as written: BOLDER BIOTECHNOLOGY, INC., BOULDER, CO. Novel drugs combinations for impr source ↗
- NIH award 5U01AI107340-05 FY2017: $476,768 awarded for that fiscal year; activity U01 (OTHER_NIH); PI COX, GEORGE NORBERT; recipient as written: BOLDER BIOTECHNOLOGY, INC., BOULDER, CO. Long-acting growth factors for source ↗
- NIH award 4U01AI107340-04 FY2016: $674,036 awarded for that fiscal year; activity U01 (OTHER_NIH); PI COX, GEORGE NORBERT; recipient as written: BOLDER BIOTECHNOLOGY, INC., BOULDER, CO. Long-acting growth factors for source ↗
- NIH award 5U01AI107340-03 FY2015: $553,403 awarded for that fiscal year; activity U01 (OTHER_NIH); PI COX, GEORGE NORBERT; recipient as written: BOLDER BIOTECHNOLOGY, INC., BOULDER, CO. Long-acting growth factors for source ↗
- NIH award 5R44AI084288-05 FY2015: $1,196,000 awarded for that fiscal year; activity R44 (SBIR); PI COX, GEORGE NORBERT; recipient as written: BOLDER BIOTECHNOLOGY, INC., BOULDER, CO. Long-Acting G-CSF Analog for Trea source ↗
- NIH award 5U01AI107340-02 FY2014: $731,319 awarded for that fiscal year; activity U01 (OTHER_NIH); PI COX, GEORGE NORBERT; recipient as written: BOLDER BIOTECHNOLOGY, INC., BOULDER, CO. Long-acting growth factors for source ↗
- NIH award 5R44AI084288-04 FY2014: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI COX, GEORGE NORBERT; recipient as written: BOLDER BIOTECHNOLOGY, INC., BOULDER, CO. Long-Acting G-CSF Analog for Trea source ↗
- NIH award 1U01AI107340-01 FY2013: $488,794 awarded for that fiscal year; activity U01 (OTHER_NIH); PI COX, GEORGE NORBERT; recipient as written: BOLDER BIOTECHNOLOGY, INC., BOULDER, CO. Long-acting growth factors for source ↗
- NIH award 2R44AI084288-03A1 FY2013: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI COX, GEORGE NORBERT; recipient as written: BOLDER BIOTECHNOLOGY, INC., BOULDER, CO. Long-Acting G-CSF Analog for Tr source ↗
- NIH award 5R43AI088928-02 FY2011: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI COX, GEORGE NORBERT; recipient as written: BOLDER BIOTECHNOLOGY, INC., BOULDER, CO. Long-Acting IL-11 Analog for Treati source ↗
- NIH award 5R44DK068949-04 FY2010: $472,707 awarded for that fiscal year; activity R44 (SBIR); PI COX, GEORGE NORBERT; recipient as written: BOLDER BIOTECHNOLOGY, INC., BOULDER, CO. Long-acting EPO analog for treating source ↗
- NIH award 5R43AI084288-02 FY2010: $299,927 awarded for that fiscal year; activity R43 (SBIR); PI COX, GEORGE NORBERT; recipient as written: BOLDER BIOTECHNOLOGY, INC., BOULDER, CO. Long-Acting G-CSF analogs for treat source ↗
- NIH award 5R43AI084301-02 FY2010: $299,943 awarded for that fiscal year; activity R43 (SBIR); PI COX, GEORGE NORBERT; recipient as written: BOLDER BIOTECHNOLOGY, INC., BOULDER, CO. GM-CSF analogs for treating acute r source ↗
- NIH award 1R43AI088928-01 FY2010: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI COX, GEORGE NORBERT; recipient as written: BOLDER BIOTECHNOLOGY, INC., BOULDER, CO. Long-Acting IL-11 Analog for Treati source ↗
- NIH award 1R43AI084288-01 FY2009: $299,958 awarded for that fiscal year; activity R43 (SBIR); PI COX, GEORGE NORBERT; recipient as written: BOLDER BIOTECHNOLOGY, INC., BOULDER, CO. Long-Acting G-CSF analogs for treat source ↗
- NIH award 2R44DK068949-03A1 FY2009: $767,785 awarded for that fiscal year; activity R44 (SBIR); PI COX, GEORGE NORBERT; recipient as written: BOLDER BIOTECHNOLOGY, INC., BOULDER, CO. Long-acting EPO analog for treati source ↗
- NIH award 1R43AI084301-01 FY2009: $299,958 awarded for that fiscal year; activity R43 (SBIR); PI COX, GEORGE NORBERT; recipient as written: BOLDER BIOTECHNOLOGY, INC., BOULDER, CO. GM-CSF analogs for treating acute r source ↗
- NIH award 5R44AI058815-03 FY2009: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI COX, GEORGE NORBERT; recipient as written: BOLDER BIOTECHNOLOGY, INC., BOULDER, CO. Long-acting Growth Hormone for Tr source ↗
- NIH award 5R44NS040205-05 FY2009: $790,800 awarded for that fiscal year; activity R44 (SBIR); PI COX, GEORGE NORBERT; recipient as written: BOLDER BIOTECHNOLOGY, INC., BOULDER, CO. Long Acting Beta Interferon for Tre source ↗
- NIH award 2R44NS040205-04 FY2008: $826,535 awarded for that fiscal year; activity R44 (SBIR); PI COX, GEORGE NORBERT; recipient as written: BOLDER BIOTECHNOLOGY, INC., BOULDER, CO. Long Acting Beta Interferon for Tre source ↗
- NIH award 2R44AI058815-02A1 FY2008: $976,501 awarded for that fiscal year; activity R44 (SBIR); PI COX, GEORGE NORBERT; recipient as written: BOLDER BIOTECHNOLOGY, INC., BOULDER, CO. Long-acting Growth Hormone for Tr source ↗
- NIH award 5R44AR051609-03 FY2008: $347,061 awarded for that fiscal year; activity R44 (SBIR); PI COX, GEORGE NORBERT; recipient as written: BOLDER BIOTECHNOLOGY, INC., BOULDER, CO. Long Acting VEGF Binding Proteins f source ↗
- NIH award 5R44AI060043-03 FY2008: $398,910 awarded for that fiscal year; activity R44 (SBIR); PI COX, GEORGE NORBERT; recipient as written: BOLDER BIOTECHNOLOGY, INC., BOULDER, CO. Long Acting IFN-gamma for Treating source ↗